Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0752, Comparator: MK0752, Notch Inhibitor
MK-0752 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | MK0752 1000 mg |
| B | ACTIVE_COMPARATOR | MK0752 350 mg |
| C | PLACEBO_COMPARATOR | Placebo |
| Part I - Arm 1 | EXPERIMENTAL | - |
| Part II - Arm 1 | EXPERIMENTAL | - |
| Part III - Arm 1 | EXPERIMENTAL | - |
| Part IV - Arm 1 | EXPERIMENTAL | - |
| Part V - Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK0752 | DRUG | Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments. |
| Comparator: MK0752. | DRUG | Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments. |
| Comparator: Placebo | DRUG | Single dose placebo capsules: there will be a 7-day washout period between treatments. |
| Comparator: MK0752, Notch Inhibitor | DRUG | Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule. |
| Comparator: MK0752, Notch Inhibitor - 450 mg | DRUG | Dose 450 mg capsules daily for 28 day cycles. |
| Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off | DRUG | Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day. |
| Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off | DRUG | Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments. |
| Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg | DRUG | Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION |
Inclusion Criteria: * Patient is a male * Patient has no clinically significant abnormality on electrocardiogram performed * Patient agrees to not to consume apple juice, grapefruit or grapefruit products beginning 2 weeks prior to first dose of study drug and for the duration of the study * Patien...
Top 20 of 91 competitors
MK0752 is an investigational small molecule being studied for advanced breast cancer and other solid tumors, as well as in healthy volunteers for biomarker research. It is a gamma secretase inhibitor that targets the Notch signaling pathway. The drug is not approved and remains in clinical development.
MK0752 targets the Notch signaling pathway as a gamma secretase inhibitor. By inhibiting gamma secretase, it blocks Notch pathway activation, which is implicated in cancer cell growth and survival. This mechanism is being explored in advanced breast cancer and other solid tumors.
MK0752 is being developed by Merck & Company, Inc., traded on the New York Stock Exchange under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
MK0752 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in advanced breast cancer and other solid tumors and another in healthy volunteers. The drug is investigational and has not received FDA approval.
MK0752 has completed two Phase 1 trials. NCT00106145 enrolled 103 patients with advanced breast cancer and other solid tumors. NCT00803894 enrolled 30 healthy male volunteers to determine biomarkers of response. Both trials are completed, and no active trials are listed.
MK0752 is a Notch inhibitor, specifically a gamma secretase inhibitor that blocks Notch signaling. It is being studied for its potential in treating advanced breast cancer and other solid tumors by targeting this pathway.